For the year ending 2025-12-31, BCLI has $1,022K in assets. $11,007K in debts. $29K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 29 | |||
| Other accounts receivable | 86 | |||
| Prepaid expenses and other current assets | 192 | |||
| Total current assets | 307 | |||
| Other long-term assets | 25 | |||
| Restricted cash | 247 | |||
| Operating lease right of use asset (note 4) | 208 | |||
| Cost | 3,437 | |||
| Accumulated depreciation | 3,202 | |||
| Property and equipment, net (note 5) | 235 | |||
| Total long-term assets | 715 | |||
| Total assets | 1,022 | |||
| Accounts payables | 7,067 | |||
| Accrued expenses | 396 | |||
| Short-term loans (note 11) | 967 | |||
| Operating lease liability (note 4) | 208 | |||
| Employees related liability | 2,369 | |||
| Total current liabilities | 11,007 | |||
| Total liabilities | 11,007 | |||
| Common stock of 0.00005 par value - authorized 250,000,000 shares at december 31, 2025 and 100,000,000 shares at december 31, 2024 respectively issued and outstanding 11,034,775 and 6,141,762 shares at december 31, 2025 and december 31, 2024 respectively | 16 | |||
| Additional paid-in-capital | 227,058 | |||
| Treasury stocks | 116 | |||
| Accumulated deficit | -236,943 | |||
| Total stockholders' deficit | -9,985 | |||
| Total liabilities and stockholders' deficit | 1,022 | |||
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)